The Ledger
Community Health Systems learns Monday at 5 p.m. New York time how many holders of its $1.24 billion junior notes will take a swap that Fitch already treats as a default. UPDATE on the debt exchange we covered November 20. The hospital operator’s early tender deadline is November 23. As of Sunday, the company’s SEC filing list shows no filing after the November 9 press release, so no early results or extension have been announced. The release itself, read as Exhibit 99.1 to the company’s 8-K, adds terms we did not report earlier. Tenders by the deadline get $1,000 of new 10.250% senior secured notes due January 15, 2035 per $1,000 of old 6.875% junior-priority secured notes due 2029, and later tenders through December 10 get $970. The offer also asks holders to consent to removing substantially all restrictive covenants from the old notes, so holders who stay out would own a weaker claim. The supporting holders, about $643.7 million or 52 percent, agreed to tender, and if less than 100 percent is tendered they will receive the untendered portion of new notes in exchange for their separate 6.125% junior-priority notes due 2030. New notes are callable at 101 from November 15, 2027 and at par from November 15, 2028. Only qualified institutional buyers can participate. One correction of emphasis: the release says the company “intends to commence” the offer, and we could not confirm from the filing alone the formal launch date, so we are not repeating that it launched November 9. Who it hits: noteholders, vendors and the communities served by the company’s 59 hospitals. The so-what: the supporters’ 52 percent is already a majority of the notes, so the number to watch is how much of the other 48 percent tenders. Confidence: High on the terms as the company states them; Low on the consent threshold, which we did not find in the release and which sits in the offering memorandum we did not read.
Capricor, the cell-therapy company the FDA just refused to approve, has about $198.5 million and says that funds operations for at least 12 months. UPDATE on the Duchenne heart therapy deramiocel that The Regulator covered this morning, here from the balance-sheet side. The company’s November 20 press release says the Food and Drug Administration (FDA) issued a Complete Response Letter, stating the agency does not consider the data sufficient to establish “substantial evidence of effectiveness” and citing “certain other clinical deficiencies.” Cash, restricted cash and marketable securities were about $198.5 million on September 30, and the company says it is “reviewing its operating costs to further extend its cash runway.” The release gives no burn rate, no resubmission timeline and no workforce figures. The company holds a call at 8:30 a.m. Eastern Monday. Who it hits: the company’s investors and partners, and anyone pricing late-stage cell-therapy rare-disease programs, where one agency letter can reset the plan. Confidence: High on the release content; Low on what happens next, because the company has not said.
Quiet note: Sunday carries no earnings from our watch list, and we found no rating action, health-system bankruptcy filing or layoff announcement that we could confirm with a November 20 to 22 date. We are not repeating the Redeemer Health and Roseland cases without new filings. Pending deals already announced, such as the Option Care Health take-private, showed no new development in this scan. Frontier scan (behavioral health, dermatology and veterinary platforms) found no deal dated this week.
THE DEAL SHEET
No new transactions spotted in the last 24 hours. Searches of trade press and deal roundups turned up only deals announced before November 20, which are already covered or outside the window.
Free. One email a day at 6pm your time, or one summary every Friday. Switch or stop anytime.